Title: Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
Abstract: HomeCirculationVol. 142, No. 19Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19 Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBEndotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19 Antoine Rauch, Annabelle Dupont, Julien Goutay, Morgan Caplan, Senna Staessens, Mouhamed Moussa, Emmanuelle Jeanpierre, Delphine Corseaux, Guillaume Lefevre, Fanny Lassalle, Karine Faure, Marc Lambert, Alain Duhamel, Julien Labreuche, Delphine Garrigue, Simon F. De Meyer, Bart Staels, Eric Van Belle, Flavien Vincent, Eric Kipnis, Peter J. Lenting, Julien Poissy, Sophie Susen and For the Lille COVID Research Network (LICORNE) Antoine RauchAntoine Rauch Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) , Annabelle DupontAnnabelle Dupont Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) , Julien GoutayJulien Goutay Intensive Care Department, Pôle de Réanimation (J.G., M.C.), Centre Hospitalier Universitaire Lille, France. , Morgan CaplanMorgan Caplan https://orcid.org/0000-0002-6016-0749 Intensive Care Department, Pôle de Réanimation (J.G., M.C.), Centre Hospitalier Universitaire Lille, France. , Senna StaessensSenna Staessens Centre national de la recherche scientifique, Surgical Critical Care, Department of Anesthesiology and Critical Care, U1019 - Unité mixte de recherche 9017 - Center for Infection and Immunity of Lille (E.K.), Institut Pasteur de Lille, UMR1011-EGID (S. Staessens, D.C., B.S.), Univ. Lille, CHU Lille, France. Laboratory for Thrombosis Research, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Belgium (S. Staessens, S.F.D.M.). , Mouhamed MoussaMouhamed Moussa Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) Surgical Critical Care, Department of Anesthesiology and Critical Care (M.M.), Univ. Lille, CHU Lille, France. , Emmanuelle JeanpierreEmmanuelle Jeanpierre Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) , Delphine CorseauxDelphine Corseaux Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) Centre national de la recherche scientifique, Surgical Critical Care, Department of Anesthesiology and Critical Care, U1019 - Unité mixte de recherche 9017 - Center for Infection and Immunity of Lille (E.K.), Institut Pasteur de Lille, UMR1011-EGID (S. Staessens, D.C., B.S.), Univ. Lille, CHU Lille, France. , Guillaume LefevreGuillaume Lefevre Institut d'Immunologie, U1286 - INFINITE - Institute for Translational Research in Inflammation (G.L.), ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales (A. Duhamel, J.L.), Univ. Lille, CHU Lille, France. , Fanny LassalleFanny Lassalle https://orcid.org/0000-0003-0494-823X Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) , Karine FaureKarine Faure Department of Infectious Diseases (K.F.), Univ. Lille, CHU Lille, France. , Marc LambertMarc Lambert Department of Internal Medicine, Institut national de la santé et de la recherche médicale U 1167 (M.L.), Univ. Lille, CHU Lille, France. , Alain DuhamelAlain Duhamel Institut d'Immunologie, U1286 - INFINITE - Institute for Translational Research in Inflammation (G.L.), ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales (A. Duhamel, J.L.), Univ. Lille, CHU Lille, France. , Julien LabreucheJulien Labreuche Institut d'Immunologie, U1286 - INFINITE - Institute for Translational Research in Inflammation (G.L.), ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales (A. Duhamel, J.L.), Univ. Lille, CHU Lille, France. , Delphine GarrigueDelphine Garrigue Surgical Critical Care, Department of Anesthesiology and Critical Care (D.G.), Centre Hospitalier Universitaire Lille, France. , Simon F. De MeyerSimon F. De Meyer Laboratory for Thrombosis Research, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Belgium (S. Staessens, S.F.D.M.). , Bart StaelsBart Staels https://orcid.org/0000-0002-3784-1503 Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) Centre national de la recherche scientifique, Surgical Critical Care, Department of Anesthesiology and Critical Care, U1019 - Unité mixte de recherche 9017 - Center for Infection and Immunity of Lille (E.K.), Institut Pasteur de Lille, UMR1011-EGID (S. Staessens, D.C., B.S.), Univ. Lille, CHU Lille, France. , Eric Van BelleEric Van Belle https://orcid.org/0000-0001-6509-443X Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) Department Cardiology (E.V.B., F.V.), Univ. Lille, CHU Lille, France. , Flavien VincentFlavien Vincent https://orcid.org/0000-0002-1007-1473 Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) , Eric KipnisEric Kipnis https://orcid.org/0000-0001-8887-7330 Centre national de la recherche scientifique, Surgical Critical Care, Department of Anesthesiology and Critical Care, U1019 - Unité mixte de recherche 9017 - Center for Infection and Immunity of Lille (E.K.), Institut Pasteur de Lille, UMR1011-EGID (S. Staessens, D.C., B.S.), Univ. Lille, CHU Lille, France. , Peter J. LentingPeter J. Lenting https://orcid.org/0000-0002-7937-3429 , Julien PoissyJulien Poissy https://orcid.org/0000-0001-6017-5353 Institut national de la santé et de la recherche médicale U1285, Pôle de réanimation, Centre national de la recherche scientifique, Unité mixte de recherche 8576 - Unité de Glycobiologie Structurale et Fonctionnelle (J.P.), Univ. Lille, CHU Lille, France. , Sophie SusenSophie Susen Sophie Susen, MD, PhD, Heart and Lung Institute, Hemostasis Department, Bd du Pr Leclercq, CHU Lille, 59037 Lille cedex, France. Email E-mail Address: [email protected] https://orcid.org/0000-0001-5953-163X Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France (A.R., A. Dupont, M.M., E.J., D.C., F.L., B.S., E.V.B., F.V., S. Susen) and For the Lille COVID Research Network (LICORNE) and Members of the LICORNE Scientific Committee Originally published24 Sep 2020https://doi.org/10.1161/CIRCULATIONAHA.120.050907Circulation. 2020;142:1881–1884Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: September 24, 2020: Ahead of Print Lung histological analyses revealed the presence of vascular inflammation and severe endothelial injury as a direct consequence of intracellular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and ensuing host inflammatory response in coronavirus disease 2019 (COVID-19).1 Endothelial cells promote coagulation following injury, leading to widespread formation of microthrombi, provoking microcirculatory failure or large-vessel thrombosis.2 Growing evidence suggests that microvascular thrombosis is a major pathophysiological event in COVID-19 pathogenesis. Damaged endothelial cells could be closely implicated in the prothrombotic state commonly reported in severe patients in the intensive care unit (ICU). How SARS-CoV-2 exerts its cytopathic effects is still a matter of debate, and ultrastructural evidence of direct viral replication in endothelial cells remains to be demonstrated. Although direct viral tissue damage is a plausible mechanism of injury,3 endothelial damage and thromboinflammation associated with dysregulated immune responses, inducing microvascular thrombosis, represent an attractive alternative hypothesis.2 Using cultured human pulmonary microvascular endothelial cells (HPMVEC), we assessed whether plasma collected from patients with COVID-19 at different disease stages could trigger endothelial damage in vitro. The cytotoxicity of plasma samples on HPMVEC was evaluated by assessing mitochondrial activity (WST-1 test) 1 hour after incubation of cells with plasma as previously described.4 We further investigated the association of plasma-induced cytotoxicity with levels of circulating biomarkers related to organ dysfunction (Pao2 [partial pressure of oxygen in arterial blood]/Fio2 [fraction of inspired oxygen], widely used as an indicator of oxygenation requirements, lactate dehydrogenase, creatinine, and aspartate transaminase), endothelial damage (von Willebrand factor antigen; ADAMTS13; plasminogen activator inhibitor-1; syndecan-1), tissue injury (cell-free DNA, a damage-associated molecular patterns marker), and levels of circulating cytokines related to the activation of innate (interleukin [IL]–6 and tumor necrosis factor–α) and adaptative immune cell responses (soluble IL-2 receptor). Inclusion criteria were individuals aged 18 years or older with a positive SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction on nasal or tracheal samples admitted to the Lille University Hospital. Patients on treatment with direct oral anticoagulant or vitamin K antagonists were switched to therapeutic heparin therapy on admission. Patients not in the ICU received once daily thromboprophylaxis with enoxaparin according to their body weight. Patients in the ICU received enoxaparin or unfractionated heparin according to their renal status, their body weight, and the need for invasive procedures. This study was approved by the French institutional authority for personal data protection (Commission Nationale de l'Informatique et des Libertés No. DEC20-086) and the ethics committee (IRB 2020-A00763-36), and informed consent was obtained from all participants.HPMVEC viability was assessed after coincubation with plasma sampled on admission from 28 consecutive patients (non-ICU, n=16; ICU, n=12) hospitalized for COVID-19 at the Lille University Hospital between March 30, 2020, and April 8, 2020, in convalescent patients with COVID-19 (n=6 from the 12 patients in the ICU) sampled after ICU discharge (mean±SD, 21±7 days) and in control healthy donors (n=8). Compared with healthy donor plasma, plasma from patients with COVID-19 significantly decreased HPMVEC viability, with plasma from patients in the ICU inducing the greatest cytotoxicity (Figure [A]). It is interesting that HPMVEC viability was partially restored to control when plasma from convalescent patients after ICU discharge was tested and compared with plasma of the same patients at the time of ICU admission. Moreover, markers of organ dysfunction were correlated with plasma-induced cytotoxicity (Figure [B]). HPMVEC viability also correlated with most plasma markers related to endothelial damage or tissue injury (Figure [C]). Soluble IL-2 receptor and tumor necrosis factor–α levels negatively correlated with HPMVEC viability (Figure [D]). Overall, the degree of vascular endothelial cell injury induced by plasma sampled from patients with COVID-19 correlated to both clinical illness severity at admission and the levels of biomarkers related to endothelial injury, tissue injury, and proinflammatory cytokines.Download figureDownload PowerPointFigure. Endothelial cell cytotoxicity induced by plasma sampled from critically ill and convalescent patients with coronavirus disease 2019 (COVID-19). The cytotoxicity of platelet-poor plasma samples (obtained after a double centrifugation of citrate tubes at 2500 g for 15 minutes at room temperature) from patients with COVID-19 and controls on HPMVEC was evaluated with a colorimetric assay using 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1.3-benzene disulfonate (WST-1), which in viable cells is cleaved by mitochondrial dehydrogenases. After incubation, the cells were washed with phosphate buffered saline and incubated with WST-1 (Roche, Basel, Switzerland) at a dilution of 1:10 (10 µL) for 2 h at 37°C. Absorbance was measured using a multiwell plate reader (Synergy HTX multi-mode plate reader, BioTek Instruments, Highland Park, VT) at 450 nm with a reference wavelength of 620 nm. As a positive control for endothelial cell injury, Shigatoxin 145 (Sigma-Aldrich, Saint Quentin Fallavier, France) was spiked in plasma from healthy adults (10 µg/mL final concentration) and incubated at 37°C for 15 minutes, before addition to HPMVECs. Experiments were performed in triplicate for each patient sample. A, HPMVEC viability after exposure to plasma sampled in healthy subjects (n=8), in non-ICU (n=16), and in ICU (n=12) on admission and in 6 convalescent patients with COVID-19 sampled after ICU discharge (mean±SD, 21±7 days). Data points represent individual sample measurements, whereas horizontal bars show the mean (±SD). Comparisons between groups were done using the Mann-Whitney U test, except for comparison between ICU and convalescent patients, where we used Wilcoxon signed-rank test on matched pairs (n=6). Correlations between HPMVEC viability and (B) markers of organ dysfunction: the Pao2/FiO2 ratio, widely used as an indicator of oxygenation requirements, LDH, creatinine and AST; (C) parameters related to endothelial dysfunction and tissue injury: VWF:Ag, ADAMTS13, ADAMTS13:VWF ratio, PAI-1, syndecan-1, and cell-free DNA; and (D) plasma cytokine concentrations: IL-2R, IL-6. and TNF-α. Correlations were evaluated with the Spearman rank-correlation statistical test. No adjustment for multiple comparisons was done, and the result should be interpreted as hypothesis-generating. AST indicates aspartate transaminase; HPMVEC, human pulmonary microvascular endothelial cells; ICU, intensive care unit; IL, interleukin; IL-2R, soluble IL-2 receptor; LDH, lactate dehydrogenase; PAI-1, plasminogen activator inhibitor-1; TNF–α, tumor necrosis factor–α; and VWF:Ag, von Willebrand factor antigen.Our data shed new light on the pathophysiology of COVID-19 by demonstrating the direct and rapid cytotoxic effect of plasma collected from critically ill patients on vascular endothelial cells. This rapid effect (1 hour after plasma exposure) excludes a direct cytopathic effect of SARS-CoV-2 infection, as the progression of viral infection and visible cytopathogenic effects are in general only apparent 12 to 24 hours after infection.5 A higher cytotoxic effect of plasma on endothelial cells was associated with a more pronounced hypoxemia and organ dysfunction as reflected by the correlation with Pao2/FiO2, lactate dehydrogenase, creatinine, and aspartate transaminase. This cytotoxic effect also correlated with circulating markers of endothelial damage, indicating that this in vitro functional assay reflects microvascular endothelial damage in vivo. Different pathways could be involved in endothelial cell injury during the course of COVID-19, ie, complement activation, cellular hypoxia, platelets, and direct cytotoxicity of cytokines such as IL-6, IL-1β, and tumor necrosis factor–α. We observed a relationship between this cytotoxic effect and the level of proinflammatory cytokines, suggesting that cytotoxicity could be related to overproduction of proinflammatory cytokines. However, this article does not provide the supportive evidence of convalescent plasma for treating severe patients with COVID-19.In conclusion, we provide for the first time the results of a functional assay demonstrating a direct effect of dysregulation of immune response on endothelial damage in COVID-19. Endotheliopathy is an essential part of the pathological response on severe COVID-19, leading to respiratory failure, multiorgan dysfunction, and thrombosis. Endothelial and microvascular damage are associated with immunopathology and may occur in parallel with intracellular SARS-CoV-2 infection.AcknowledgmentsThe authors thank all physicians and medical staff involved in patient care. Special thanks are addressed to Eric Boulleaux, Laureline Bourgeois, Aurélie Jospin, Catherine Marichez, Vincent Dalibard, Bénédicte Pradines, Sandrine Vanderziepe, and all the biologists and technicians of the Hemostasis Department for their support during the COVID-19 pandemic. A.R. and A. Dupont collected clinical data, analyzed the data, and wrote the article. J.G., M.C., S. Staessens, M.D.M., E.J., D.C., G.L., F.L., K.F., M.L., D.G., S.D.M., and J.P. collected data. J.G., M.C., S. Staessens, E.J., and S.D.M. analyzed the data. J.L. and A. Duhamel performed the statistical analysis. B.S., E.V., F.V., J.P., E.K., and P.L. provided critical input in the interpretation of data and critically reviewed the article. S. Susen designed the study, analyzed the data, wrote, and critically reviewed the article. All authors provided editorial review and assisted in writing the article.Sources of FundingThis study was supported by the French government through the Program Investissement d'Avenir (I-SITE ULNE/ANR-16-IDEX-0004 ULNE).DisclosuresNone.Footnotes*Drs Rauch and Dupont contributed equally.https://www.ahajournals.org/journal/circ†A list of all members of the LICORNE scientific committee is given in the Appendix.Data sharing: The data that support the findings of this study are available from the corresponding author upon request.Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT-04327180.Sophie Susen, MD, PhD, Heart and Lung Institute, Hemostasis Department, Bd du Pr Leclercq, CHU Lille, 59037 Lille cedex, France. Email [email protected]. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.N Engl J Med. 2020; 383:120–128. doi: 10.1056/NEJMoa2015432CrossrefMedlineGoogle Scholar2. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, et al. Extrapulmonary manifestations of COVID-19.Nat Med. 2020; 26:1017–1032. doi: 10.1038/s41591-020-0968-3CrossrefMedlineGoogle Scholar3. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, et al. Multiorgan and renal tropism of SARS-CoV-2.N Engl J Med. 2020; 383:590–592. doi: 10.1056/NEJMc2011400CrossrefMedlineGoogle Scholar4. Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome.Blood. 2015; 125:3637–3646. doi: 10.1182/blood-2015-02-629683CrossrefMedlineGoogle Scholar5. Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, Cinatl J, Münch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature. 2020; 583:469–472. doi: 10.1038/s41586-020-2332-7CrossrefMedlineGoogle ScholarAppendixMembers of the LICORNE Scientific Committee:Dominique Deplanque (Clinical Investigation Center, CHU Lille, France) Karine Faure (Department of Infectious Diseases, CHU Lille, France) Guillaume Lefevre (Department of Immunology, CHU Lille, France) Enagnon Kazali Alidjinou (Department of Virology, CHU Lille, France) Régis Bordet (Department of Medical Pharmacology, CHU Lille, France) Marie-Charlotte Chopin (Department of Infectious Diseases, CHU Lille, France) Ilka Engelmann (Department of Virology, CHU Lille, France) Delphine Garrigue (Department of Emergency, CHU Lille, France) Anne Goffard (Department of Virology, CHU Lille, France) Eric Kipnis (Department of Anesthesia and Critical Care, CHU Lille, France) Myriam Labalette (Department of Immunology, CHU Lille, France) Marc Lambert (Department of Internal Medicine, CHU Lille, France) David Launay (Department of Internal Medicine, CHU Lille, France) Daniel Mathieu (Department of Intensive Care, CHU Lille, France) Claude-Alain Maurage (Department of Anatomopathology, CHU Lille, France) Julien Poissy (Department of Intensive Care, CHU Lille, France) Boualem Sendid (Department of Parasitology, CHU Lille, France) Sophie Susen (Department of Hematology, CHU Lille, France) eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Zhang K, Long Y, Li S, Zhao Y and Han H (2024) Inhalable biomimetic nanomotor for pulmonary thrombus therapy, Nano Today, 10.1016/j.nantod.2024.102171, 55, (102171), Online publication date: 1-Apr-2024. de Maistre E, Savard P and Guinot P (2023) COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation, Journal of Clinical Medicine, 10.3390/jcm12237245, 12:23, (7245) Gouzi F, Philippe A, Pastre J, Renaud B, Gendron N, Subileau M, Hua-Huy T, Planquette B, Sanchez O, Smadja D and Günther S (2023) Recovery of Endothelium-dependent vascular relaxation impairment in convalescent COVID-19 patients: Insight from a pilot study, Respiratory Medicine and Research, 10.1016/j.resmer.2023.101044, 84, (101044), Online publication date: 1-Nov-2023. Jones E (2023) Mechanism of COVID-19-Induced Cardiac Damage from Patient, In Vitro and Animal Studies, Current Heart Failure Reports, 10.1007/s11897-023-00618-w, 20:5, (451-460), Online publication date: 1-Oct-2023. Kondo R, Iwakiri Y, Kage M and Yano H (2023) Endotheliopathy of liver sinusoidal endothelial cells in liver disease, Pathology International, 10.1111/pin.13361, 73:9, (381-393), Online publication date: 1-Sep-2023. Zhao J, Xie Y, Meng Z, Liu C, Wu Y, Zhao F, Ma X, Christopher T, Lopez B and Wang Y (2023) COVID-19 and cardiovascular complications: updates of emergency medicine, Emergency and Critical Care Medicine, 10.1097/EC9.0000000000000095, 3:3, (104-114), Online publication date: 1-Sep-2023. Guérin E, Belin L, Franchineau G, Le Guennec L, Hajage D, Diallo M, Frapard T, Le Fèvre L, Luyt C, Combes A, Germain S, Hayon J, Asfar P and Bréchot N (2023) FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial, Critical Care, 10.1186/s13054-023-04616-1, 27:1 Escaffre O, Szaniszlo P, Törő G, Vilas C, Servantes B, Lopez E, Juelich T, Levine C, McLellan S, Cardenas J, Freiberg A and Módis K (2023) Hydrogen Sulfide Ameliorates SARS-CoV-2-Associated Lung Endothelial Barrier Disruption, Biomedicines, 10.3390/biomedicines11071790, 11:7, (1790) Elhadad S, Redmond D, Tan A, Huang J, Rodriguez B, Racine-Brzostek S, Subrahmanian S, Ahamed J and Laurence J (2023) Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies, Thrombosis Research, 10.1016/j.thromres.2023.03.009, 225, (47-56), Online publication date: 1-May-2023. Xiang M, Wu X, Jing H, Novakovic V and Shi J (2023) The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2023.1062491, 10 Shu H, Wen Z, Li N, Zhang Z, Ceesay B, Peng Y, Zhou N and Wang D (2023) COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations, Aging and disease, 10.14336/AD.2023.0314, 14:6, (2071), . Cognasse F, Hamzeh-Cognasse H, Rosa M, Corseaux D, Bonneaudeau B, Pierre C, Huet J, Arthaud C, Eyraud M, Prier A, Duchez A, Ebermeyer T, Heestermans M, Audoux-Caire E, Philippot Q, Le Voyer T, Hequet O, Fillet A, Chavarin P, Legrand D, Richard P, Pirenne F, Gallian P, Casanova J, Susen S, Morel P, Lacombe K, Bastard P and Tiberghien P (2023) Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study, eBioMedicine, 10.1016/j.ebiom.2022.104414, 87, (104414), Online publication date: 1-Jan-2023. Khan A, Reyat J, Hill H, Bourne J, Colicchia M, Newby M, Allen J, Crispin M, Youd E, Murray P, Taylor G, Stamataki Z, Richter A, Cunningham A, Pugh M and Rayes J (2022) Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature, Cardiovascular Research, 10.1093/cvr/cvac097, 118:15, (3085-3096), Online publication date: 9-Dec-2022. Birhanu A, Ayana G, Merga B, Alemu A, Negash B, Seid A and Dessie Y (2022) Incidence and predictors of organ failure among COVID-19 hospitalized adult patients in Eastern Ethiopia. Hospital-based retrospective cohort study, BMC Infectious Diseases, 10.1186/s12879-022-07402-6, 22:1, Online publication date: 1-Dec-2022. Rovas A, Buscher K, Osiaevi I, Drost C, Sackarnd J, Tepasse P, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Rossaint J, Vink H, Lukasz A, Pavenstädt H and Kümpers P (2022) Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study, Angiogenesis, 10.1007/s10456-022-09843-8, 25:4, (503-515), Online publication date: 1-Nov-2022. Amri N, Tessier N, Bégin R, Vachon L, Bégin P, Bazin R, Loubaki L and Martel C (2022) Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy, Cells, 10.3390/cells11193122, 11:19, (3122) Voelkel N, Bogaard H and Kuebler W (2022) ARDS in the time of corona: context and perspective, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00432.2021, 323:4, (L431-L437), Online publication date: 1-Oct-2022. Davidson S, Lukhna K, Gorog D, Salama A, Castillo A, Giesz S, Golforoush P, Kalkhoran S, Lecour S, Imamdin A, do Carmo H, Bovi T, Perroud M, Ntsekhe M, Sposito A and Yellon D (2021) RIC in COVID-19—a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19, Cardiovascular Drugs and Therapy, 10.1007/s10557-021-07221-y, 36:5, (925-930), Online publication date: 1-Oct-2022. Xiang M, Wu X, Jing H, Liu L, Wang C, Wang Y, Novakovic V and Shi J (2022) The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors, Frontiers in Immunology, 10.3389/fimmu.2022.955654, 13 Hetland G, Fagerhol M, Wiedmann M, Søraas A, Mirlashari M, Nissen-Meyer L, Istre M, Holme P and Schultz N (2022) Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects, Vaccines, 10.3390/vaccines10081267, 10:8, (1267) Palomo M, Youssef L, Ramos A, Torramade-Moix S, Moreno-Castaño A, Martinez-Sanchez J, Bonastre L, Pino M, Gomez-Ramirez P, Martin L, Garcia Mateos E, Sanchez P, Fernandez S, Crovetto F, Escolar G, Carreras E, Castro P, Gratacos E, Crispi F and Diaz-Ricart M (2022) Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy, American Journal of Obstetrics and Gynecology, 10.1016/j.ajog.2022.03.048, 227:2, (277.e1-277.e16), Online publication date: 1-Aug-2022. Gorog D, Storey R, Gurbel P, Tantry U, Berger J, Chan M, Duerschmied D, Smyth S, Parker W, Ajjan R, Vilahur G, Badimon L, Berg J, Cate H, Peyvandi F, Wang T and Becker R (2022) Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium, Nature Reviews Cardiology, 10.1038/s41569-021-00665-7, 19:7, (475-495), Online publication date: 1-Jul-2022. Chilosi M, Doglioni C, Ravaglia C, Martignoni G, Salvagno G, Pizzolo G, Bronte V and Poletti V (2022) Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia, Biomedicines, 10.3390/biomedicines10061332, 10:6, (1332) Muhl L, He L, Sun Y, Andaloussi Mäe M, Pietilä R, Liu J, Genové G, Zhang L, Xie Y, Leptidis S, Mocci G, Stritt S, Osman A, Anisimov A, Hemanthakumar K, Räsänen M, Hansson E, Björkegren J, Vanlandewijck M, Blomgren K, Mäkinen T, Peng X, Hu Y, Ernfors P, Arnold T, Alitalo K, Lendahl U and Betsholtz C (2022) The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research, Stem Cell Reports, 10.1016/j.stemcr.2022.03.016, 17:5, (1089-1104), Online publication date: 1-May-2022. Olschewski H, Eber E, Bucher B, Hackner K, Handzhiev S, Hoetzenecker K, Idzko M, Klepetko W, Kovacs G, Lamprecht B, Löffler-Ragg J, Meilinger M, Müller A, Prior C, Schindler O, Täubl H, Zacharasiewicz A, Zwick R, Arns B, Bolitschek J, Cima K, Gingrich E, Hochmair M, Horak F, Jaksch P, Kropfmüller R, Pfleger A, Puchner B, Puelacher C, Rodriguez P, Salzer H, Schenk P, Stelzmüller I, Strenger V, Urban M, Wagner M, Wimberger F and Flick H (2022) Management of pat